CSIMarket
 


Regulus Therapeutics Inc   (RGLS)
Other Ticker:  
 

Regulus Therapeutics Inc 's Tangible Leverage Ratio

RGLS's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -1.68%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 0.34, below the Regulus Therapeutics Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 182 other companies have achieved lower Tangible Leverage Ratio than Regulus Therapeutics Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 372 to 600 .

Explain Tangible Leverage Ratio?
What is RGLS Market Share?
What are RGLS´s Total Liabilities?


RGLS Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -28.74 % -19.72 % -46.03 % 14.89 % 7.84 %
Y / Y Total Liabilities Change -23.83 % -19.12 % -11.27 % -4.31 % -1.82 %
Tangible Leverage Ratio MRQ 0.34 0.28 0.39 0.4 0.31
RGLS's Total Ranking # 600 # 372 # 860 # 935 # 1079
Seq. Tangible Equity Change -16.89 % 27.96 % -20.14 % -16.09 % -6.37 %
Seq. Total Liabilities Change -1.68 % -7.39 % -22.38 % 7.77 % 4.41 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 183
Healthcare Sector # 313
Overall Market # 600


Tangible Leverage Ratio Statistics
High Average Low
21.03 1.39 0.12
(Sep 30 2018)   (Mar 31 2015)




Financial Statements
Regulus Therapeutics Inc 's Tangible Equity $ 28 Millions Visit RGLS's Balance sheet
Regulus Therapeutics Inc 's Total Liabilities $ 9 Millions Visit RGLS's Balance sheet
Source of RGLS's Sales Visit RGLS's Sales by Geography


Cumulative Regulus Therapeutics Inc 's Tangible Leverage Ratio

RGLS's Tangible Leverage Ratio for the trailling 12 Months

RGLS Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -28.74 % -19.72 % -46.03 % 14.89 % 7.84 %
Y / Y Total Liabilities TTM Growth -23.83 % -19.12 % -11.27 % -4.31 % -1.82 %
Tangible Leverage Ratio TTM 0.35 0.34 0.34 0.3 0.31
Total Ranking TTM # 680 # 795 # 790 # 658 # 3
Seq. Tangible Equity TTM Growth -16.89 % 27.96 % -20.14 % -16.09 % -6.37 %
Seq. Total Liabilities TTM Growth -1.68 % -7.39 % -22.38 % 7.77 % 4.41 %


On the trailing twelve months basis Despite of the repayements of liabilities of -1.68% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.35, below Regulus Therapeutics Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 189, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Regulus Therapeutics Inc . While Tangible Leverage Ratio total ranking has improved so far to 680, from total ranking in previous 12 month period at 795.

Explain Tangible Leverage Ratio?
What is RGLS Market Share?
What are RGLS´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 190
Healthcare Sector # 339
Within the Market # 680


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
1496.07 46.3 0.13
(Mar 31 2019)   (Dec. 30, 2015)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Prophase Labs Inc   0.92 $ 35.282  Millions$ 38.182  Millions
Spero Therapeutics Inc   0.92 $ 49.276  Millions$ 53.705  Millions
Acadia Pharmaceuticals Inc   0.92 $ 270.366  Millions$ 295.319  Millions
Unity Biotechnology Inc   0.91 $ 33.064  Millions$ 36.206  Millions
Harmony Biosciences Holdings inc   0.88 $ 296.434  Millions$ 338.263  Millions
Igm Biosciences Inc   0.87 $ 220.488  Millions$ 253.862  Millions
Verastem inc   0.86 $ 71.814  Millions$ 83.180  Millions
Onconova Therapeutics inc   0.86 $ 12.521  Millions$ 14.517  Millions
Pulmatrix Inc   0.85 $ 16.889  Millions$ 19.881  Millions
Aptevo Therapeutics Inc   0.84 $ 12.411  Millions$ 14.718  Millions
Longeveron Inc   0.83 $ 3.394  Millions$ 4.093  Millions
Rhythm Pharmaceuticals inc   0.82 $ 156.725  Millions$ 190.232  Millions
Acurx Pharmaceuticals inc   0.82 $ 3.223  Millions$ 3.935  Millions
Organogenesis Holdings Inc   0.80 $ 185.782  Millions$ 230.992  Millions
Geovax Labs Inc   0.78 $ 7.082  Millions$ 9.119  Millions
Abvc Biopharma Inc   0.77 $ 6.985  Millions$ 9.062  Millions
Neximmune Inc   0.76 $ 6.308  Millions$ 8.254  Millions
Cartesian Therapeutics Inc   0.76 $ 45.705  Millions$ 60.329  Millions
Macrogenics Inc   0.75 $ 145.992  Millions$ 193.980  Millions
23andme Holding Co  0.75 $ 175.979  Millions$ 235.672  Millions
Hutchmed china Limited  0.74 $ 549.232  Millions$ 743.387  Millions
Therapeuticsmd Inc   0.73 $ 15.701  Millions$ 21.395  Millions
Gain Therapeutics inc  0.71 $ 5.182  Millions$ 7.331  Millions
Alkermes Plc   0.68 $ 845.096  Millions$ 1,251.723  Millions
Vyne Therapeutics Inc   0.67 $ 7.762  Millions$ 11.505  Millions
Hepion Pharmaceuticals inc   0.67 $ 8.732  Millions$ 12.969  Millions
Guardion Health Sciences Inc   0.67 $ 5.176  Millions$ 7.702  Millions
Vincerx Pharma Inc   0.67 $ 10.535  Millions$ 15.741  Millions
Elite Pharmaceuticals Inc   0.66 $ 25.625  Millions$ 38.753  Millions
Acasti Pharma Inc   0.66 $ 11.465  Millions$ 17.479  Millions

Date modified: 2023-11-12T04:56:09+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com